An experimental therapeutic cancer vaccine with a dual mode of action has passed its first clinical hurdle and will continue to be investigated as a first-line therapy in patients with metastatic non-small cell lung cancer (NSCLC). The vaccine, IO102 is being developed by IO Biotech ApS of Denmark in combination with Keytruda. An interim Phase 2 analysis, designed as a futility analysis, showed that the vaccine delivered an objective response rate that was substantially higher than Keytruda monotherapy had done in patients with a similar profile.
